Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COSTAR LUNG in advanced non-small cell lung cancer after prior PD-(L)1 therapy and chemotherapy
NL-OMON60897Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Mar 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cobolimab, dostarlimab and docetaxel in non-small cell lung cancer (NSCLC), sponsored by GSK. Primary endpoints: Overall survival for triplet versus docetaxel and Overall survival for doublet versus docetaxel. Started Mar 2022; status: active, not recruiting.
02
Drugs
cobolimabdostarlimabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60897.